Radiopharma companies merge after one receives surprise FDA rejection - STAT
Why now
Thesis: FDA rejection driving radiopharma consolidation shows regulatory risk
Catalyst to watch: FDA decisions or further radiopharma M&A
Main risk: Regulatory setbacks derailing niche biotech deals
Why it matters
Radiopharma merger after an FDA rejection shows regulatory risk driving consolidation in a niche biotech segment.
Sources
- googlenews · news.google.com · 2026-09-20 23:28 UTC